Swiss National Bank Has $32.27 Million Holdings in United Therapeutics Co. (NASDAQ:UTHR)

Swiss National Bank decreased its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 2.6% in the 4th quarter, HoldingsChannel.com reports. The firm owned 146,755 shares of the biotechnology company’s stock after selling 3,900 shares during the period. Swiss National Bank’s holdings in United Therapeutics were worth $32,270,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in UTHR. Fisher Asset Management LLC lifted its position in United Therapeutics by 3.1% during the 4th quarter. Fisher Asset Management LLC now owns 3,731 shares of the biotechnology company’s stock worth $820,000 after buying an additional 112 shares in the last quarter. First Trust Direct Indexing L.P. increased its position in shares of United Therapeutics by 14.0% in the fourth quarter. First Trust Direct Indexing L.P. now owns 1,527 shares of the biotechnology company’s stock valued at $336,000 after acquiring an additional 187 shares during the last quarter. New York Life Investment Management LLC raised its holdings in United Therapeutics by 4.4% during the fourth quarter. New York Life Investment Management LLC now owns 5,644 shares of the biotechnology company’s stock worth $1,241,000 after acquiring an additional 238 shares in the last quarter. Victory Capital Management Inc. boosted its position in United Therapeutics by 309.7% during the fourth quarter. Victory Capital Management Inc. now owns 134,162 shares of the biotechnology company’s stock valued at $29,501,000 after purchasing an additional 101,419 shares during the last quarter. Finally, Jackson Creek Investment Advisors LLC acquired a new position in United Therapeutics during the fourth quarter valued at approximately $683,000. Institutional investors own 94.08% of the company’s stock.

Insider Transactions at United Therapeutics

In other United Therapeutics news, Director Christopher Causey sold 2,240 shares of the company’s stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $259.91, for a total transaction of $582,198.40. Following the completion of the sale, the director now directly owns 4,185 shares in the company, valued at $1,087,723.35. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other United Therapeutics news, Director Christopher Causey sold 2,240 shares of the business’s stock in a transaction dated Friday, May 3rd. The stock was sold at an average price of $259.91, for a total transaction of $582,198.40. Following the completion of the transaction, the director now owns 4,185 shares of the company’s stock, valued at $1,087,723.35. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Martine A. Rothblatt sold 15,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $236.59, for a total transaction of $3,548,850.00. Following the completion of the sale, the chief executive officer now owns 130 shares in the company, valued at $30,756.70. The disclosure for this sale can be found here. In the last 90 days, insiders sold 147,630 shares of company stock valued at $35,089,803. Company insiders own 12.50% of the company’s stock.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR opened at $266.22 on Wednesday. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.77 and a quick ratio of 3.64. The firm has a market cap of $11.81 billion, a price-to-earnings ratio of 12.59 and a beta of 0.54. The stock’s fifty day moving average price is $238.38 and its two-hundred day moving average price is $229.88. United Therapeutics Co. has a one year low of $204.44 and a one year high of $266.65.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $6.17 EPS for the quarter, topping analysts’ consensus estimates of $5.63 by $0.54. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The firm had revenue of $677.70 million for the quarter, compared to analyst estimates of $620.31 million. During the same quarter last year, the company earned $4.86 EPS. The company’s revenue was up 33.7% on a year-over-year basis. On average, equities analysts forecast that United Therapeutics Co. will post 23.88 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on UTHR. Leerink Partnrs reiterated an “outperform” rating on shares of United Therapeutics in a research note on Monday, February 5th. Wells Fargo & Company upped their price target on shares of United Therapeutics from $309.00 to $325.00 and gave the stock an “overweight” rating in a research report on Thursday, March 7th. HC Wainwright reissued a “buy” rating and issued a $300.00 price objective on shares of United Therapeutics in a research report on Thursday, May 2nd. The Goldman Sachs Group upped their target price on shares of United Therapeutics from $218.00 to $240.00 and gave the company a “neutral” rating in a report on Friday, May 3rd. Finally, SVB Leerink started coverage on United Therapeutics in a report on Monday, February 5th. They set an “outperform” rating and a $330.00 price target for the company. One analyst has rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $308.78.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.